Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMMX Immix Biopharma, Inc.

Post-Mkt 03-17 16:08:06 EDT

11.12

+0.35

+3.25%

盘后11.34

+0.22+1.98%

16:04 EDT

High11.61	Low10.58	Vol979.73K
Open10.84	D1 Closing10.77	Amplitude9.56%
Mkt Cap588.86M	Tradable Cap460.81M	Total Shares52.96M
T/O11.09M	T/O Rate2.36%	Tradable Shares41.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMMX","market":"US","secType":"STK","nameCN":"Immix Biopharma, Inc.","latestPrice":11.12,"timestamp":1773777600000,"preClose":10.77,"halted":0,"volume":979727,"hourTrading":{"tag":"盘后","latestPrice":11.34,"preClose":11.12,"latestTime":"16:04 EDT","volume":2765,"amount":30785.52106,"timestamp":1773777899678,"change":0.22,"changeRate":0.019784,"amplitude":0.019784},"delay":0,"changeRate":0.03249767873723302,"floatShares":41439399,"shares":52955100,"eps":-0.777635,"marketStatus":"Post-Mkt","change":0.35,"latestTime":"03-17 16:08:06 EDT","open":10.835,"high":11.6099,"low":10.58,"amount":11086784.90568,"amplitude":0.095627,"askPrice":11.75,"askSize":5,"bidPrice":11,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.777635,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773792000000},"marketStatusCode":4,"adr":0,"listingDate":1639630800000,"exchange":"NASDAQ","adjPreClose":10.77,"preHourTrading":{"tag":"盘前","latestPrice":10.75,"preClose":10.77,"latestTime":"09:29 EDT","volume":1926,"amount":20930.700996,"timestamp":1773754199999,"change":-0.02,"changeRate":-0.001857,"amplitude":0.13649},"postHourTrading":{"tag":"盘后","latestPrice":11.34,"preClose":11.12,"latestTime":"16:04 EDT","volume":2765,"amount":30785.52106,"timestamp":1773777899678,"change":0.22,"changeRate":0.019784,"amplitude":0.019784},"volumeRatio":1.342981,"impliedVol":0.9301,"impliedVolPercentile":0.239},"requestUrl":"/m/hq/s/IMMX","defaultTab":"news","newsList":[{"id":"2618640333","title":"Immix Biopharma Initiated at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640333","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640333?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:53","pubTimestamp":1773053580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 06:53 ET (10:53 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2618649223","title":"Immix Biopharma initiated with an Outperform at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2618649223","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618649223?lang=en_us&edition=fundamental","pubTime":"2026-03-09 16:50","pubTimestamp":1773046220,"startTime":"0","endTime":"0","summary":"Citizens initiated coverage of Immix Biopharma (IMMX) with an Outperform rating and $23 price target The firm says the company’s NXC-201 has demons...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-initiated-with-an-outperform-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-initiated-with-an-outperform-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2617598947","title":"Immix Biopharma Publishes Corporate Presentation on NXC-201 BCMA CAR-T for Relapsed/Refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2617598947","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617598947?lang=en_us&edition=fundamental","pubTime":"2026-03-05 08:18","pubTimestamp":1772669934,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc. released a corporate presentation outlining its focus on NXC-201, a BCMA-targeted CAR-T therapy being studied for relapsed or refractory AL amyloidosis. The presentation states that relapsed or refractory AL amyloidosis has no FDA-approved therapies and cites an estimated 38,500 relapsed or refractory patients in the U.S. It also summarizes clinical data presented at ASH in December 2025, including a reported 75 percent complete response rate for NXC-201 in this setting, and describes planned clinical and commercial milestones, including a registrationally designed NEXICART-2 trial and a commercial launch plan in the first half of 2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL9k8Tsz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2616227323","title":"Immix Biopharma to Present and Host Investor Meetings at Leerink Partners Global Healthcare Conference and Citizens Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2616227323","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616227323?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:45","pubTimestamp":1772545512,"startTime":"0","endTime":"0","summary":"Immix Biopharma to Present and Host Investor Meetings at Leerink Partners Global Healthcare Conference and Citizens Life Sciences Conference","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL1m1bVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","MNSH","BK4139","BK4588","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","NDAQ","SG9999014039.USD","BK4207","IE00BGHQF748.EUR","SG9999014021.USD","LU2210150020.SGD","BK4112","IMMX","LU2095319765.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2611488042","title":"Immix Biopharma (IMMX) Gets a Buy from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2611488042","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611488042?lang=en_us&edition=fundamental","pubTime":"2026-02-16 20:16","pubTimestamp":1771244194,"startTime":"0","endTime":"0","summary":"In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Immix Biopharma, with a price target of $14.00. Acc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/immix-biopharma-immx-gets-a-buy-from-mizuho-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/immix-biopharma-immx-gets-a-buy-from-mizuho-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMMX","BK4139","BK4207","MFG"],"gpt_icon":0},{"id":"2610632857","title":"Immix Biopharma Inc : Mizuho Initiates Coverage With Outperform Rating; Price Target $14","url":"https://stock-news.laohu8.com/highlight/detail?id=2610632857","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610632857?lang=en_us&edition=fundamental","pubTime":"2026-02-09 19:37","pubTimestamp":1770637053,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nFWN3Z50LX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2609683399","title":"Immix Biopharma Inc. unveils new presentation on relapsed/refractory AL amyloidosis treatment challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2609683399","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609683399?lang=en_us&edition=fundamental","pubTime":"2026-02-05 00:51","pubTimestamp":1770223862,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on February 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDLb0QrVr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2606805712","title":"BUZZ-Immix climbs on FDA's 'breakthrough' tag for blood disorder therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2606805712","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606805712?lang=en_us&edition=fundamental","pubTime":"2026-01-28 22:01","pubTimestamp":1769608891,"startTime":"0","endTime":"0","summary":"BUZZ-Immix climbs on FDA's 'breakthrough' tag for blood disorder therapy** Shares of Immix Biopharma IMMX.O rise 4.4% to $6.20 premarket** Co says the U.S. FDA has granted a 'breakthrough therapy' designation to NXC-201 for the treatment of AL Amyloidosis, a type of blood disorder** A breakthrough therapy tag is meant to speed up development and review of drugs to treat a serious condition or unmet medical need** Says the tag is based on mid-stage trial results of NXC-201 ** Co plans to submit marketing application for the therapy this year** AL amyloidosis is a rare and serious blood-related disorder where abnormal proteins build up in vital organs, interfering with their function** As of last close, stock has more than tripled in the last 12 months  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nL4N3YT1KV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2606714464","title":"FDA Grants Breakthrough Therapy Designation to Immix Biopharma's NXC-201 for AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2606714464","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606714464?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:45","pubTimestamp":1769607912,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on January 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL2kWV5R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BGHQF748.EUR","SG9999014021.USD","IE00BKPKM429.USD","BK4588","IMMX","SG9999014013.SGD","LU0314104364.USD","BK4112","LU2210150020.SGD","SG9999014005.SGD","LU2210149790.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","BK4585","NDAQ"],"gpt_icon":0},{"id":"2606714951","title":"Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for Nxc-201","url":"https://stock-news.laohu8.com/highlight/detail?id=2606714951","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606714951?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:45","pubTimestamp":1769607900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nTUA3D7WJP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2606714905","title":"Immix Biopharma Inc: Final Data Expected This Year Followed by Planned Bla Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2606714905","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606714905?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:45","pubTimestamp":1769607900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nTUA3D7WJP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2603544343","title":"Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2603544343","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603544343?lang=en_us&edition=fundamental","pubTime":"2026-01-12 23:48","pubTimestamp":1768232880,"startTime":"0","endTime":"0","summary":"Immix Biopharma Inc (NASDAQ: IMMX) shares are trading lower Monday after the company filed a new shelf registration statement.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/12/Blue-Candlestick-Stock-Chart-With-Market.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/12/Blue-Candlestick-Stock-Chart-With-Market.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49848420/immix-biopharma-immx-shares-slip-as-investors-focus-on-plans-to-offer-and-sell-750-million-in-securities","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49848420/immix-biopharma-immx-shares-slip-as-investors-focus-on-plans-to-offer-and-sell-750-million-in-securities","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["ISBC","IMMX","BK4139","BK4211"],"gpt_icon":0},{"id":"2602302496","title":"BRIEF-Immix Biopharma To Offer And Sell Up To $750 Million In Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2602302496","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602302496?lang=en_us&edition=fundamental","pubTime":"2026-01-10 07:18","pubTimestamp":1768000720,"startTime":"0","endTime":"0","summary":"BRIEF-Immix Biopharma To Offer And Sell Up To $750 Million In Securities - SEC FilingJan 9  - Immix Biopharma Inc IMMX.O:IMMIX BIOPHARMA INC - TO OFFER AND SELL UP TO $750 MILLION IN SECURITIES - SEC FILINGSource text: [ID:n0001493152-26-001159]Further company coverage: IMMX.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nFWN3YA1S0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2602302311","title":"Immix Biopharma files $750M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2602302311","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602302311?lang=en_us&edition=fundamental","pubTime":"2026-01-10 06:30","pubTimestamp":1767997815,"startTime":"0","endTime":"0","summary":"17:29 EST Immix Biopharma (IMMX) files $750M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immix-biopharma-files-750m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immix-biopharma-files-750m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2602930406","title":"Immix Biopharma Inc - to Offer and Sell up to $750 Mln in Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2602930406","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602930406?lang=en_us&edition=fundamental","pubTime":"2026-01-10 06:30","pubTimestamp":1767997806,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nFWN3YA1S0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMMX","BK4139"],"gpt_icon":0},{"id":"2602430494","title":"Immix Biopharma Inc. unveils presentation on relapsed/refractory AL amyloidosis treatment challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2602430494","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602430494?lang=en_us&edition=fundamental","pubTime":"2026-01-10 06:12","pubTimestamp":1767996770,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDLblHpZl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2590551333","title":"Immix Biopharma CEO Ilya Rachman Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590551333","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590551333?lang=en_us&edition=fundamental","pubTime":"2025-12-11 07:49","pubTimestamp":1765410593,"startTime":"0","endTime":"0","summary":"Ilya M. Rachman, CEO and Chairman of Immix Biopharma Inc., has reported the acquisition of common shares of Immix Biopharma Inc., according to a recent regulatory filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL8nZV0Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Immix Biopharma CEO Ilya Rachman Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2590551809","title":"Immix Biopharma CFO Gabriel S. Morris Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590551809","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590551809?lang=en_us&edition=fundamental","pubTime":"2025-12-11 07:47","pubTimestamp":1765410469,"startTime":"0","endTime":"0","summary":"Gabriel S. Morris, Chief Financial Officer and Director of Immix Biopharma Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL5db4Tx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2590732745","title":"BRIEF-Immix Biopharma Announces Closing Of Upsized $100 Million Underwritten Offering Of Common Stock And Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2590732745","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590732745?lang=en_us&edition=fundamental","pubTime":"2025-12-10 06:52","pubTimestamp":1765320735,"startTime":"0","endTime":"0","summary":"BRIEF-Immix Biopharma Announces Closing Of Upsized $100 Million Underwritten Offering Of Common Stock And Pre-Funded WarrantsDec 9 (Reuters) - Immix Biopharma Inc IMMX.O:IMMIX BIOPHARMA ANNOUNCES CLOS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA88X000:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"gpt_icon":0},{"id":"2590534099","title":"Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2590534099","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590534099?lang=en_us&edition=fundamental","pubTime":"2025-12-09 23:42","pubTimestamp":1765294920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 10:42 ET (15:42 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immixbio.com","stockEarnings":[{"period":"1week","weight":0.0632},{"period":"1month","weight":0.4693},{"period":"3month","weight":0.8131},{"period":"6month","weight":4.4949},{"period":"1year","weight":5.5273},{"period":"ytd","weight":1.0593}],"compareEarnings":[{"period":"1week","weight":-0.0136},{"period":"1month","weight":-0.0187},{"period":"3month","weight":-0.0145},{"period":"6month","weight":0.0149},{"period":"1year","weight":0.1887},{"period":"ytd","weight":-0.0189}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.035123},{"month":2,"riseRate":0.2,"avgChangeRate":-0.05746},{"month":3,"riseRate":0.2,"avgChangeRate":-0.024293},{"month":4,"riseRate":0.5,"avgChangeRate":-0.026863},{"month":5,"riseRate":0.5,"avgChangeRate":0.112474},{"month":6,"riseRate":0.5,"avgChangeRate":0.09241},{"month":7,"riseRate":0.5,"avgChangeRate":0.015932},{"month":8,"riseRate":0.25,"avgChangeRate":-0.104667},{"month":9,"riseRate":0.25,"avgChangeRate":0.017421},{"month":10,"riseRate":0.75,"avgChangeRate":0.171445},{"month":11,"riseRate":1,"avgChangeRate":0.264693},{"month":12,"riseRate":1,"avgChangeRate":0.380003}],"exchange":"NASDAQ","name":"Immix Biopharma, Inc.","nameEN":"Immix Biopharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immix Biopharma, Inc.,IMMX,Immix Biopharma, Inc.股票,Immix Biopharma, Inc.股票老虎,Immix Biopharma, Inc.股票老虎国际,Immix Biopharma, Inc.行情,Immix Biopharma, Inc.股票行情,Immix Biopharma, Inc.股价,Immix Biopharma, Inc.股市,Immix Biopharma, Inc.股票价格,Immix Biopharma, Inc.股票交易,Immix Biopharma, Inc.股票购买,Immix Biopharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immix Biopharma, Inc.(IMMX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immix Biopharma, Inc.(IMMX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}